About: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis
Creator	Flynn, Patricia Becker, Cornelia Buell, Donald Denning, David Facklam, David Lau, Wendi Marr, Kieren Patterson, Thomas Ratanatharathorn, Voravit Seibel, Nita Ullmann, Andrew Van Burik, Jo-Anne
source	Elsevier; Medline; PMC
abstract	Summary Background Micafungin (FK463) is a new lipopeptide compound (echinocandin) with activity against Aspergillus and Candida species. This study evaluated the safety and efficacy of micafungin in patients with proven or probable invasive aspergillosis (IA). Methods A multinational, non-comparative study was conducted to examine proven or probable (pulmonary only) Aspergillus species infection in a wide variety of patient populations. The study employed an open-label design utilizing micafungin alone or in combination with another systemic antifungal agent. Criteria for IA and therapeutic responses were judged by an independent panel. Results Of the 331 patients enrolled, only 225 met diagnostic criteria for IA as determined by the independent panel and received at least one dose of micafungin. Patients included 98/225 who had undergone hematopoietic stem cell transplantation (HSCT) (88/98 allogeneic), 48 with graft versus host disease (GVHD), and 83/225 who had received chemotherapy for hematologic malignancy. A favorable response rate at the end of therapy was seen in 35.6% (80/225) of patients. Of those only treated with micafungin, favorable responses were seen in 6/12 (50%) of the primary and 9/22 (40.9%) of the salvage therapy group, with corresponding numbers in the combination treatment groups of 5/17 (29.4%) and 60/174 (34.5%) of the primary and salvage treatment groups, respectively. Of the 326 micafungin-treated patients, 183 (56.1%) died during therapy or in the 6-week follow-up phase; 107 (58.5%) deaths were attributable to IA. Conclusions Micafungin as primary or salvage therapy proved efficacious and safe in high-risk patients with IA, although patient numbers are small in the micafungin-only groups.
has issue date	2006-11-30(xsd:dateTime)
bibo:doi	10.1016/j.jinf.2006.03.003
bibo:pmid	16678903
has license	els-covid
sha1sum (hex)	6ccbb562bbdca61165bb27cec24934d51dc91de4
schema:url	https://doi.org/10.1016/j.jinf.2006.03.003
resource representing a document's title	Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis
has PubMed Central identifier	PMC7132396
has PubMed identifier	16678903
schema:publication	Journal of Infection
resource representing a document's body	covid:6ccbb562bbdca61165bb27cec24934d51dc91de4#body_text
is schema:about of	named entity 'INVASIVE ASPERGILLOSIS' named entity 'TREATMENT' named entity 'ANTIFUNGAL AGENTS' named entity 'responses' named entity 'independent' named entity 'dose' named entity 'SYSTEMIC' named entity 'DIAGNOSTIC CRITERIA' named entity 'NUMBERS' named entity 'DETERMINED BY' named entity '60%' named entity 'DIED' named entity '2856' named entity 'RESPONSES' named entity 'RECEIVED' named entity 'GRAFT VERSUS HOST DISEASE' named entity 'ATTRIBUTABLE' named entity 'ANTIFUNGAL AGENT' named entity 'FOLLOW-UP' named entity 'CONCLUSIONS' named entity '326' named entity 'TREATED WITH' named entity 'PRIMARY' named entity '225' named entity 'COMBINATION' named entity 'THERAPY' named entity 'AT THE END' named entity '107' named entity 'SALVAGE THERAPY' named entity 'FAVORABLE' named entity 'PATIENT' named entity 'WEEK' named entity 'COMBINATION' named entity 'CHEMOTHERAPY' named entity 'INCLUDED' named entity 'HEMATOLOGIC MALIGNANCY' covid:arg/6ccbb562bbdca61165bb27cec24934d51dc91de4 named entity 'TREATED' named entity '183' named entity 'SEEN' named entity 'THERAPY GROUP' named entity 'FAVORABLE RESPONSE' named entity 'SAFE' named entity 'ACUTE' named entity 'GROUPS' named entity 'HIGH-RISK' named entity 'HEMATOPOIETIC STEM CELL TRANSPLANTATION' named entity 'RESULTS' named entity 'RESPONSE RATE' named entity 'PHASE' named entity 'SALVAGE' named entity 'PATIENTS' named entity 'THERAPEUTIC' named entity 'DOSE' named entity '35.6' named entity '2880' named entity 'TREATMENT' named entity 'ALLOGENEIC' named entity 'SMALL' named entity 'CRITERIA' named entity 'INDEPENDENT' named entity 'MICAFUNGIN' named entity 'PANEL' named entity 'MET' named entity 'MICAFUNGIN' named entity 'ENROLLED' named entity 'SYSTEMIC' named entity 'independent' named entity 'antifungal agent' named entity 'GVHD'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software